Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

54.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,160
Open 54.63
Bid (Size) 52.79 (1)
Ask (Size) 53.50 (20)
Prev. Close 54.63
Today's Range 54.63 - 54.63
52wk Range 20.84 - 75.00
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the... 
Via StockStory
Topics Stocks
Exposures US Equities
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill

Performance

YTD
+9.3%
+9.3%
1 Month
-9.8%
-9.8%
3 Month
+7.4%
+7.4%
6 Month
+18.0%
+18.0%
1 Year
+112.2%
+112.2%

More News

Read More
3 Growth Stocks in Hot Water
Via StockStory
1 Small-Cap Stock on Our Buy List and 2 to Avoid
Via StockStory
Earnings Scheduled For February 26, 2025
Via Benzinga
Exploring NASDAQ:CORT's high growth characteristics.
Via Chartmill
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
Via Chartmill
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
From Corcept Therapeutics Incorporated
Via Business Wire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
NASDAQ:CORT is not too expensive for the growth it is showing.
Via Chartmill
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Why Corcept (CORT) Shares Are Sliding Today
Via StockStory
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics
Via Business Wire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
Via Chartmill
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Via StockStory
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
Via Chartmill
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Investors should take note of NASDAQ:CORT, a growth stock that remains attractively priced.
Via Chartmill
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes
Via Benzinga
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
From Corcept Therapeutics Incorporated
Via Business Wire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 54.63
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 03/28/25 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 6.33B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.